Microsatellite Instability (MSI)
Microsatellite Instability (MSI) status is among the first truly histology agnostic biomarkers relevant to guide immunotherapy, critical to precision medicine approaches in clinical oncology.
- In comparison to traditional PCR, which typically interrogates only 5 microsatellite loci, OnkoSight AdvancedTM NGS targets a total of 130 homopolymer sites. An accumulation of data suggests that MSI calling by PCR may demonstrate inferior accuracy and technical sensitivity when only a small number of loci are examined.8
A comprehensive testing strategy for both TMB and tumor-only MSI is now recognized as an emerging standard of care for contemporary genomic profiling of advanced solid organ malignancies. Conjunctional NGS MSI testing eliminates the requirement for iterative testing approaches and mitigates risk of tissue depletion in scant specimens. 9-10